Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

Research questions effectiveness of MS medications in slowing disability progression

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not receiving treatment.

25 Sep 2024

Study reveals biomarkers that predict disability worsening in multiple sclerosis

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).

19 Sep 2024

Early intervention in pediatric-onset MS can lead to improved long-term outcomes

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term disability in multiple sclerosis (MS) patients.

18 Sep 2024

Review highlights mitochondrial dysfunction in cholestatic liver injury

Bile acids are essential signaling molecules derived from cholesterol metabolism in the liver and are crucial for the digestion and absorption of fats.

16 Sep 2024

New insights into stiff-person syndrome, advancing diagnosis and treatment

Research explores the complexities of diagnosing and treating stiff-person syndrome, emphasizing the uncertain role of GAD antibodies and the promise of novel therapies.

5 Sep 2024

Study reveals how light-activated macrophages increase their appetite for cancer cells

The body has a veritable army constantly on guard to keep us safe from microscopic threats from infections to cancer.

12 Aug 2024

Exercise enhances efficacy of antibody therapy in leukemia patients

Bouts of moderate-to-vigorous intensity exercise could improve the efficacy of antibody therapies used to treat chronic lymphocytic leukemia, new research has shown.

21 May 2024

Research highlights emergence of immune-evasive SARS-CoV-2 variants in immunocompromised patients

New research to be presented at next week's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) highlights the risk of new immune-evasive SARS-CoV-2 variants emerging in immunocompromised patients.

18 Apr 2024

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.

10 Apr 2024

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

From Sino Biological Inc. 5 Apr 2024

Study reveals safety of MS drugs during breastfeeding in child's early years of life

Certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child during the first three years of life, according to a preliminary study released today, March 4, 2024.

4 Mar 2024

Study offers insights into who's at risk for long COVID among immunocompromised patients

Early in the pandemic, clinicians noticed that certain immunocompromised patients were experiencing persistent SARS-CoV-2 infections, some lasting weeks to months at a time.

26 Jan 2024

Mice with humanized immune systems test new cancer therapeutic approach that blindfolds immune cells to the body’s self-recognition system

Researchers investigated the anticancer effects of drugs targeting human tumor-associated macrophages (TAMs) in vivo. In humanized murine models, they tested the effectiveness of an antibody to human signal regulatory protein alpha (SIRPα) for cancer immunotherapy.

19 Dec 2023

T-cells step up to offer protection against COVID-19 in B-cell deficient patients

B cell deficiency is a common condition that can result either from immunosuppressant drugs used to treat autoimmune disease or certain cancers -; such as rituximab (RTX) -; or from natural immune deficiency.

18 Dec 2023

Researchers develop humanized mouse model for macrophage-targeted cancer immunotherapy

Mice with human immune cells are a new way of testing anti-cancer drugs targeting the immune system in pre-clinical studies.

14 Dec 2023

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a 'surprisingly high' response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11 Dec 2023

Research redefines rheumatoid arthritis: Over 314,000 cells analyzed for precise treatment strategies

A new paper recently published in Nature, reported the examination of synovial tissue from the joints of nearly 80 people with RA, in combination with RNA sequencing and surface protein analyses.

10 Nov 2023

Study provides evidence for combination therapy as first-line treatment for relapsed ITP

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, conducted a multicenter comprehensive retrospective analysis to assess the effectiveness and safety of primary single-agent and combination therapies in treating adult patients with relapsed immune thrombocytopenia (ITP).

9 Oct 2023

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.

1 Aug 2023